<DOC>
	<DOCNO>NCT02541942</DOCNO>
	<brief_summary>This study conduct globally . This study describe pharmacogenetic test saliva sample patient participate NN1731-3562 trial ( adept™2 ) ( NCT01392547 ) . The objective determine HLA ( human leukocyte antigen ) type polymorphism FVII gene patient previously expose rFVIIa analogue .</brief_summary>
	<brief_title>Pharmacogenetic Testing Saliva Samples From Patients With Five More Exposure Days rFVIIa Analogue Adept™2 Trial</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Informed consent obtain collection saliva sample Previous participation adept™2 trial 5 exposure day rFVIIa analogue</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>